
Ascendis Pharma A/SNASDAQ - ASND
Reports
Search reports
Name | Reporting Date | Filing Date |
---|
2024-12-31 20-F | 2024-12-31 | 2025-02-12 |
2023-12-31 20-F | 2023-12-31 | 2024-02-07 |
2022-12-31 20-F | 2022-12-31 | 2023-02-16 |
2021-12-31 20-F | 2021-12-31 | 2022-03-02 |
2020-12-31 20-F | 2020-12-31 | 2021-03-10 |
2019-12-31 20-F | 2019-12-31 | 2020-04-03 |
2018-12-31 20-F | 2018-12-31 | 2019-04-03 |
2017-12-31 20-F | 2017-12-31 | 2018-03-28 |
2016-12-31 20-F | 2016-12-31 | 2017-03-22 |
2015-12-31 20-F | 2015-12-31 | 2016-04-15 |
2014-12-31 20-F | 2014-12-31 | 2015-03-26 |
1
20 / page
About
Name
Ascendis Pharma A/S
Overview
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Show More
CEO
Mr. Jan Moller Mikkelsen
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2015-01-28
Address
Tuborg Boulevard 12, Hellerup, 2900, Denmark
Tel
45-70-22-22-44
Website